Seroprevalence of Pertussis Among Children and Adolescents in Croatia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-15

Study Completion Date

2022-09-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pertussis is a vaccine preventable disease caused by Bordetella pertussis. Older children and adolescents with pertussis continue to be a significant source of infection for incompletely vaccinated infants who are in harm for developing severe disease. The primary objective of our study is to estimate the duration of protection elicited by the current vaccination schedule against pertussis in Croatia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pertussis Challenge Study in Adults Vaccinated With BPZE1

NCT05461131

Pertussis/Whooping Cough Bordetella Pertussis, Whooping Cough

COMPLETED PHASE2

A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation with Bordetella Pertussis Using Controlled Human Infection

NCT06903221

Pertussis Infection Pertussis Vaccines

RECRUITING PHASE4

Immunising Mums Against Pertussis 3

NCT03578120

Whooping Cough Maternal Vaccine Exposure Immunization; Infection

COMPLETED

Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

NCT03147898

Whooping Cough Pertussis

COMPLETED

Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women

NCT05264662

dTap Vaccine

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunogenicity, Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Seroprevalence of pertussis among children and adolescents in Croatia

For all patients participating in the study one serum sample will be collected for serological analysis.

Group Type OTHER

ELISA IgG Testkit

Intervention Type DIAGNOSTIC_TEST

All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ELISA IgG Testkit

All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children and adolescents from 6 to 18 years of age treated through Emergency room and/or Day hospital of Pediatric Infectious Diseases Department at UHID;
* appropriate vaccination with pertussis component containing vaccine by date and at the appropriate time, according to Croatian NIP proven by insight in the Vaccination Record Card
* written informed consent obtained from the subject's parent or caregiver, as well as from participants ≥ 16 years old.

Exclusion Criteria

* children under 6 years
* children and adolescents with acute respiratory symptoms
* children and adolescents with pertussis-like illness within 12 months
* children and adolescents with unknown, uncompleted or irregular vaccination record
* inpatients
* children and adolescents with immunodeficiencies

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No